{
    "root": "65cfb382-8f01-4ee8-8235-8ce2f5d3beec",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rivastigmine Tartrate",
    "value": "20250303",
    "ingredients": [
        {
            "name": "RIVASTIGMINE TARTRATE",
            "code": "9IY2357JPE"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        }
    ],
    "indications": "Rivastigmine tartrate capsules are an acetylcholinesterase inhibitor indicated for treatment of: • Mild-to-moderate dementia of the Alzheimer’s type (AD) ( 1.1 ) • Mild-to-moderate dementia associated with Parkinson’s disease (PD) ( 1.2 )",
    "contraindications": "Alzheimer’s Disease ( 2.1 ) : • Initial Dose: Initiate treatment with 1.5 mg twice a day. • Dose Titration: After a minimum of 2 weeks, if tolerated, increase dose to 3 mg twice a day and further to 4.5 mg twice a day and 6 mg twice a day if tolerated with a minimum of 2 weeks at each dose Parkinson’s Disease Dementia (PDD) ( 2.2 ) : • Initial Dose: Initiate treatment with 1.5 mg twice a day. • Dose Titration: After a minimum of 4 weeks, if tolerated, increase dose to 3 mg twice a day and further to 4.5 mg twice a day and 6 mg twice a day if tolerated with a minimum of 4 weeks at each dose. Rivastigmine tartrate capsules should be taken with meals in divided doses in the morning and evening ( 2.1 , 2.2 ). Rivastigmine tartrate oral solution and rivastigmine tartrate capsules may be interchanged at equal doses ( 2.4 ).",
    "warningsAndPrecautions": "Rivastigmine tartrate capsules, USP equivalent to 1.5 mg, 3 mg, 4.5 mg, or 6 mg of rivastigmine base are available as follows:\n                     \n                      Rivastigmine Tartrate  Capsules USP, 1.5 mg are yellow cap and yellow body colored size ‘2’ capsules imprinted in black ink with ‘H’ on cap and ‘67’ on body, containing white to off-white granular powder.\n                     Cartons of 100 capsules (10 capsules each blister pack x 10), NDC 0904-7107-61\n                     \n                      Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Store in a tight container.",
    "adverseReactions": "Rivastigmine tartrate capsules are contraindicated in patients with:\n                  \n                     \n                        •known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see Description (11)]\n                     \n                     \n                        •a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see Warnings and Precautions (5.2)]\n                     \n                  \n                  Isolated cases of generalized skin reactions have been described in postmarketing experience [see Adverse Reactions (6.2)]."
}